Kenneth Kelley - Halozyme Therapeutics Independent Chairman of the Board
| HALO Stock | USD 38.77 0.20 0.52% |
Chairman
Mr. Kenneth J. Kelley, Ph.D., is an Independent Director of the Company. Mr. Kelley brings over 35 years of entrepreneurial, VC, operational and technical biotechnology experience to Halozyme. He is currently an Executive Chairman and mentor to the CEOs of three privately held biotechnology companies and an advisor to various publicly held biotechnology companies. From 2015 to 2018, Mr. Kelley served as a Trustee of the Sabin Vaccine Institute and led its RD Subcommittee. From 2016 to 2017, Mr. Kelley served as a White House Presidential Executive Fellow and a Senior Advisor to the U.S. National Institutes of Health and the National Institute of Allergy and Infectious Diseases, Vaccine Research Center and to the Assistant Secretary of Preparedness and Response. From 2015 to 2016, Mr. Kelley served as an Advanced Leadership Fellow at Harvard University working on global preparedness for epidemics and pandemics. From 2007 to 2015, Mr. Kelley served as the Chief Executive Officer of privatelyheld PaxVax, Inc., a specialty vaccine company acquired by Emergent BioSolutions, Inc. Previously, Mr. Kelley was a General Partner at Latterell Venture Partners, where he made investments in early stage biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in 1994 and for over eight years served as CEO, Director and Chair of the Board of Directors. Earlier, Mr. Kelley was an Associate at Institutional Venture Partners, where he participated in the financing of biotech and medical companies. Prior to IVP, he was a consultant for McKinsey Company and a scientist at Integrated Genetics since 2015.
| Age | 58 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 12390 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 794 8889 |
| Web | https://halozyme.com |
Halozyme Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 2.2207 %, meaning that it created $2.2207 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of April 2024, Return On Tangible Assets is likely to grow to 0.35. Also, Return On Capital Employed is likely to grow to 0.22. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 30th of April 2024, Fixed Asset Turnover is likely to grow to 16.71, while Non Currrent Assets Other are likely to drop about 9 M.Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Daniel Lynch | Blueprint Medicines Corp | 60 | |
| Michael Jensen | Ascendis Pharma AS | 41 | |
| John Oyler | BeiGene | 56 | |
| Pierre Lapalme | Biomarin Pharmaceutical | 73 | |
| Donald Hayden | Insmed Inc | 61 | |
| Tillman Gerngross | Alector | 60 | |
| Stelios Papadopoulos | Exelixis | 76 | |
| MD FACP | Edgewise Therapeutics | 64 | |
| Xiaodong Wang | BeiGene | 61 | |
| Leonard Gage | Cytokinetics | 75 | |
| MPH Coles | Cerevel Therapeutics Holdings | 64 | |
| John Clarke | Alnylam Pharmaceuticals | 63 | |
| Gerald Chan | Apellis Pharmaceuticals | 66 | |
| Harold Selick | Protagonist Therapeutics | 63 | |
| JeanJacques Bienaime | Biomarin Pharmaceutical | 64 | |
Management Performance
| Return On Equity | 2.22 | ||||
| Return On Asset | 0.12 |
Halozyme Therapeutics Leadership Team
Elected by the shareholders, the Halozyme Therapeutics' board of directors comprises two types of representatives: Halozyme Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Halozyme. The board's role is to monitor Halozyme Therapeutics' management team and ensure that shareholders' interests are well served. Halozyme Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Halozyme Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Posard, Director | ||
| Mark Esq, Senior Officer | ||
| Harry Leonhardt, Senior Vice President Chief Compliance Officer, General Counsel | ||
| Jim Mazzola, Vice President Corporate Communication & Investor Relations | ||
| Dimitrios Chondros, Senior Vice President Chief Commercial Officer | ||
| Randal Kirk, Independent Director | ||
| Mark Gergen, COO, Senior Vice President | ||
| Alison Armour, Senior Vice President - Research and Development | ||
| Gary Grote, Chief Officer | ||
| Helen Torley, President CEO, Director | ||
| Laurie Stelzer, CFO and Sr. VP | ||
| Jeffrey Henderson, Director | ||
| Kenneth Kelley, Independent Chairman of the Board | ||
| Amy Fox, Senior Resources | ||
| James Daly, Director | ||
| Athena Countouriotis, Chief Medical Officer | ||
| Todd Butler, VP CEO | ||
| Christopher Bryant, Chief Operations | ||
| Bernadette Connaughton, Director | ||
| Kristin Schwartzbauer, Head Quality | ||
| Benjamin Hickey, Chief Commercial Officer | ||
| Nicole LaBrosse, CFO Director | ||
| MD MBA, Chief Officer | ||
| Jim Daly, Director | ||
| Cortney MBA, Chief Officer | ||
| Kathryn Falberg, Independent Director | ||
| Connie Matsui, Independent Director | ||
| Al Kildani, Vice President Investor Relations & Corporate Communications | ||
| Michael LaBarre, Senior Officer | ||
| JeanPierre Bizzari, Independent Director | ||
| Steve MBBS, Chief Officer | ||
| Schond Greenway, Executive Director, Investor Relations & Strategy | ||
| MRCP B, CEO President | ||
| Tram Bui, Head Communications |
Halozyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Halozyme Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 2.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 6.09 B | ||||
| Shares Outstanding | 127.05 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 99.00 % | ||||
| Number Of Shares Shorted | 8.24 M | ||||
| Price To Earning | 60.08 X |
Halozyme Therapeutics Investors Sentiment
The influence of Halozyme Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Halozyme. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Halozyme Therapeutics' public news can be used to forecast risks associated with an investment in Halozyme. The trend in average sentiment can be used to explain how an investor holding Halozyme can time the market purely based on public headlines and social activities around Halozyme Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Halozyme Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Halozyme Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Halozyme Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Halozyme Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Halozyme Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Halozyme Therapeutics' short interest history, or implied volatility extrapolated from Halozyme Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.546 | Earnings Share 2.1 | Revenue Per Share 6.286 | Quarterly Revenue Growth 0.267 | Return On Assets 0.1189 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.